Abstract:Background This study aimed to understand the clinical characteristics and outcomes of children with Langerhans cell histiocytosis (LCH) in China. Methods We conducted a retrospective study of 95 paediatric patients with LCH in West China Second University Hospital of Sichuan University between July 2013 and August 2020. Results The onset age of multisystem LCH (MS-LCH) patients with risk organ (RO) involvement was younger than that of MS-LCH without RO involvement (p = .002) and single system LCH (p < .001) patients; bone was the most frequently involved organ, followed by the skin. Of all, the BRAF-V600E mutation was detected in 48 out of 84 patients who underwent gene analysis. Additionally, in our study, BRAF p.N486_T491 > K, BRAF p.L485_P490delinsF, BRAF p.R506_K507insLLR, ARAF p.Q349_F351delinsL and MAP2K1 p.Q58_E62del were known mutations in the mitogen-activated protein kinase (MAPK) pathway. The BRAF-V600E genotype in the tissue and plasma prior to therapy were detected in 16 patients, and the concordance was only 37.5% (6/16). According to the modified LCH-III-based-protocol, JLSG-02 protocol chemotherapy, and vemurafenib, the estimated five-year overall survival, event-free survival (EFS) and cumulative reactivation rates of 95 patients were 98.8%, 74.6% and 24.5%, respectively. The EFS rate in good responders was better than that in poor responders at 12-week (HR = 0.022, 95%CI 0.002-0.231, p = .002), and EFS was not affected by age, RO involvement or BRAF-V600E mutation. Regarding sequelae, nine patients had central diabetes insipidus and two had growth retardation. Conclusions In this study, LCH was a highly heterogeneous disease characterized molecularly by MAPK-pathway activating mutations. Vincristine, prednisone and cytarabine-based chemotherapy combined with vemurafenib improved the prognosis of childhood LCH. In future, prospective clinical trials and novel therapeutic strategies should be developed to improve outcomes in paediatric patients with LCH. KEY MESSAGE Children with Langerhans cell histiocytosis in China present highly heterogeneous clinical characteristics, with up to 60% of cases harbouring mutations in MAPK pathway. Treatment response at 12-week is associated with EFS in our study. Vincristine, prednisone and cytarabine-based chemotherapy combined with vemurafenib improved the prognosis of Chinese childhood LCH, but the reactivation rate is still high.

BRAFV600E and MAP2K1 Mutations in Langerhans Cell Histiocytosis Occur Predominantly in Children

The study of BRAF V600E and MAP2K1 gene mutations in Langerhans cell histiocytosis and its significance of clinical findings

Clinical Study of MAP2K1-mutated Langerhans Cell Histiocytosis in Children.

Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis.

BRAF V600E Mutation in Pediatric Langerhans Cell Histiocytosis and its Clinical Significance

[BRAF-V600E Mutation and Its Clinical Significance in Children with Langerhans Cell Histiocytosis].

Mutually Exclusive Recurrent Somatic Mutations in MAP2K1 and BRAF Support a Central Role for ERK Activation in LCH Pathogenesis

BRAF V600E Mutation in Cell-Free DNA, Rather Than in Lesion Tissues, at Diagnosis is an Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis.

A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children

Data from <i>braf</i><sup>v600e</sup> Mutation in Cell-Free DNA, Rather Than in Lesion Tissues, at Diagnosis is an Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis

BRAF‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF V 600 E-Mutated Langerhans Cell Histiocytosis

Clinical and Prognostic Characteristics of 95 Cases of Langerhans Cell Histiocytosis in Children: a Single-Institute Experience from 2013 to 2020

BRAFV600E Mutation Correlates with Suppressive Tumor Immune Microenvironment and Reduced Disease-Free Survival in Langerhans Cell Histiocytosis

Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study

Langerhans Cell Histiocytosis in Adolescent Patients: a Single-Centre Retrospective Study

BRAF deletion in adult patients with Langerhans cell histiocytosis correlates with multisystem disease and poor outcome

High Prevalence of BRAF V600E Mutations in Langerhans Cell Histiocytosis of Head and Neck in Chinese Patients

Clinical Features and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Macrophage Activation Syndrome-Hemophagocytic Lymphohistiocytosis.

A Novel Fusion Gene PLEKHA6-NTRK3 in Langerhans Cell Histiocytosis

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level